979 related articles for article (PubMed ID: 26395832)
1. Scientific rationale behind the development and approval of biosimilar infliximab (CT-P13) in Europe.
Müller-Ladner U; Hong S; Oh C; Taylor P
Expert Rev Clin Immunol; 2015; 11 Suppl 1():S5-14. PubMed ID: 26395832
[TBL] [Abstract][Full Text] [Related]
2. Analysis of clinical trials of biosimilar infliximab (CT-P13) and comparison against historical clinical studies with the infliximab reference medicinal product.
Yoo DH; Oh C; Hong S; Park W
Expert Rev Clin Immunol; 2015; 11 Suppl 1():S15-24. PubMed ID: 26395833
[TBL] [Abstract][Full Text] [Related]
3. A scientific update on biosimilar infliximab (CT-P13) in rheumatic diseases.
Taylor P
Expert Rev Clin Immunol; 2015; 11 Suppl 1():S1-4. PubMed ID: 26395831
[TBL] [Abstract][Full Text] [Related]
4. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.
Braun J; Kudrin A
Immunotherapy; 2015; 7(2):73-87. PubMed ID: 25713985
[TBL] [Abstract][Full Text] [Related]
5. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study.
Park W; Yoo DH; Jaworski J; Brzezicki J; Gnylorybov A; Kadinov V; Sariego IG; Abud-Mendoza C; Escalante WJ; Kang SW; Andersone D; Blanco F; Hong SS; Lee SH; Braun J
Arthritis Res Ther; 2016 Jan; 18():25. PubMed ID: 26795209
[TBL] [Abstract][Full Text] [Related]
6. Biosimilar infliximab for inflammatory bowel disease: from concepts to clinical practice. Case study illustrated with CT-P13.
Schreiber S; Panés J; Kwon B; Hong S; Peyrin-Biroulet L
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():5-15. PubMed ID: 26395530
[TBL] [Abstract][Full Text] [Related]
7. The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13.
Reinisch W; Louis E; Danese S
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():17-26. PubMed ID: 26395531
[TBL] [Abstract][Full Text] [Related]
8. Biosimilars for the management of rheumatoid arthritis: economic considerations.
Gulácsi L; Brodszky V; Baji P; Kim H; Kim SY; Cho YY; Péntek M
Expert Rev Clin Immunol; 2015; 11 Suppl 1():S43-52. PubMed ID: 26395836
[TBL] [Abstract][Full Text] [Related]
9. The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?
Ben-Horin S; Heap GA; Ahmad T; Kim H; Kwon T; Chowers Y
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():27-34. PubMed ID: 26395532
[TBL] [Abstract][Full Text] [Related]
10. CT-P13 in the treatment of rheumatoid arthritis.
Yoo DH
Expert Rev Clin Immunol; 2017 Jul; 13(7):653-666. PubMed ID: 28571501
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the pharmacokinetics and safety of three formulations of infliximab (CT-P13, EU-approved reference infliximab and the US-licensed reference infliximab) in healthy subjects: a randomized, double-blind, three-arm, parallel-group, single-dose, Phase I study.
Park W; Lee SJ; Yun J; Yoo DH
Expert Rev Clin Immunol; 2015; 11 Suppl 1():S25-31. PubMed ID: 26395834
[TBL] [Abstract][Full Text] [Related]
12. CT-P13: design, development, and place in therapy.
Gabbani T; Deiana S; Annese V
Drug Des Devel Ther; 2017; 11():1653-1661. PubMed ID: 28652703
[TBL] [Abstract][Full Text] [Related]
13. Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases.
Blair HA; Deeks ED
BioDrugs; 2016 Oct; 30(5):469-480. PubMed ID: 27650650
[TBL] [Abstract][Full Text] [Related]
14. Biosimilar infliximab: an expert view.
Genazzani A; Altomare G; Balato N; Cusano F; De Pità O; Loconsole F; Micali G; Piaserico S; Girolomoni G
G Ital Dermatol Venereol; 2015 Aug; 150(4):449-59. PubMed ID: 25747260
[TBL] [Abstract][Full Text] [Related]
15. A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability.
Becciolini A; Raimondo MG; Crotti C; Agape E; Biggioggero M; Favalli EG
Drug Des Devel Ther; 2017; 11():1969-1978. PubMed ID: 28721016
[TBL] [Abstract][Full Text] [Related]
16. A 5-year Retrospective Analysis of Drug Survival, Safety, and Effectiveness of the Infliximab Biosimilar CT-P13 in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis.
Kim TH; Lee SS; Park W; Song YW; Suh CH; Kim S; Lee YN; Yoo DH
Clin Drug Investig; 2020 Jun; 40(6):541-553. PubMed ID: 32328979
[TBL] [Abstract][Full Text] [Related]
17. The rise of biosimilars: potential benefits and drawbacks in rheumatoid arthritis.
Yoo DH
Expert Rev Clin Immunol; 2014 Aug; 10(8):981-3. PubMed ID: 24961712
[TBL] [Abstract][Full Text] [Related]
18. Biosimilar Monoclonal Antibodies for Inflammatory Bowel Disease: Current Comfort and Future Prospects.
Gecse KB; Lakatos PL
Drugs; 2016 Oct; 76(15):1413-1420. PubMed ID: 27638739
[TBL] [Abstract][Full Text] [Related]
19. Biosimilars in Dermatology: Current Situation (Part II).
Puig L; Carretero G; Daudén E; Ferrándiz C; Marrón SE; Martorell A; Pérez-Suárez B; Rodriguez-Cerdeira C; Ruiz-Villaverde R; Sánchez-Carazo JL; Velasco M;
Actas Dermosifiliogr; 2015 Sep; 106(7):550-4. PubMed ID: 26049964
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.
Yoo DH; Prodanovic N; Jaworski J; Miranda P; Ramiterre E; Lanzon A; Baranauskaite A; Wiland P; Abud-Mendoza C; Oparanov B; Smiyan S; Kim H; Lee SJ; Kim S; Park W
Ann Rheum Dis; 2017 Feb; 76(2):355-363. PubMed ID: 27130908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]